# MetaVia Inc.: overview MTVA · Nasdaq · CIK 1638287 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/mtva.md) · [Financials](/companies/mtva/financials.md) · [Filings](/companies/mtva/filings.md) · [Insiders](/companies/mtva/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.55)](/filings/0001104659-25-107726.md) | not reported | [(3.93)](/filings/0001104659-26-061166.md) | [(2.87)](/filings/0001104659-26-092051.md) | [(0.14)](/filings/0001104659-25-107726.md) | not reported | [(0.79)](/filings/0001104659-26-061166.md) | [(0.90)](/filings/0001104659-26-092051.md) | | Free cash flow | $k | [(5,548) d](/filings/0001104659-25-107726.md) | [(5,469) d](/filings/0001104659-26-034911.md) | not reported | not reported | [(2,955) d](/filings/0001104659-25-107726.md) | [(4,860) d](/filings/0001104659-26-034911.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(19.81)](/filings/0001558370-23-005127.md) | [(43.42)](/filings/0001558370-24-004246.md) | [(2.46)](/filings/0001558370-25-003386.md) | [(39.13)](/filings/0001104659-26-034911.md) | [(7.35)](/filings/0001104659-26-034911.md) | | Free cash flow | $m | [(15.1)](/filings/0001558370-23-005127.md) | not reported | [(10.8)](/filings/0001558370-25-003386.md) | [(24.7)](/filings/0001104659-26-034911.md) | [(15.7)](/filings/0001104659-26-034911.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mtva/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $176.7k | 123,583 | | Added +112,680 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $87.5k | 61,206 | | New +61,206 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $30.5k | 21,314 | | Reduced −12,321 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $18.5k | 12,948 | | Added +12,947 | | [Scientech Research LLC](/funds/2011556.md) | 2026-06-30 | $17.2k | 12,014 | | New +12,014 | | [Aries Wealth Management](/funds/1729515.md) | 2026-06-30 | $14.3k | 10,000 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.8k | 8,919 | | Added +6,697 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $9.9k | 6,940 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.2k | 2,223 | | Reduced −379 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $386 | 270 | | Added +65 | ## Recent filings [All 629 filings](/companies/mtva/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 09:01 ET | [8-K](/filings/0001104659-26-119401.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-119401 | | 2026-10-13 | 08:35 ET | [8-K](/filings/0001104659-26-115300.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-115300 | | 2026-09-09 | 09:00 ET | [8-K](/filings/0001104659-26-106156.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-106156 | | 2026-08-06 | 16:26 ET | [10-Q](/filings/0001104659-26-092051.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092051 | | 2026-08-06 | 16:05 ET | [8-K](/filings/0001104659-26-091981.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-091981 | | 2026-07-09 | 08:35 ET | [8-K](/filings/0001104659-26-082116.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-082116 | | 2026-07-02 | 16:06 ET | [8-K](/filings/0001104659-26-080316.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-080316 | | 2026-06-08 | 16:00 ET | [8-K](/filings/0001104659-26-071358.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-071358 | | 2026-06-08 | 09:01 ET | [8-K](/filings/0001104659-26-071211.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-071211 | | 2026-05-27 | 09:01 ET | [8-K](/filings/0001104659-26-066631.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-066631 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-034911.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1638287 - Tickers: MTVA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 09:02 ET. No prices; not investment advice.